

Alix E Seif

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3257052/publications.pdf>

Version: 2024-02-01

138
papers

3,824
citations

159525

30
h-index

133188

59
g-index

141
all docs

141
docs citations

141
times ranked

6493
citing authors

#	ARTICLE	IF	CITATIONS
1	Early stool microbiome and metabolome signatures in pediatric patients undergoing allogeneic hematopoietic cell transplantation. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29384.	0.8	8
2	Optimized amplification of BK polyomavirus in urine. <i>Journal of Virological Methods</i> , 2022, 299, 114319.	1.0	2
3	Incidence and risk factors for hypoglycemia during maintenance chemotherapy in pediatric acute lymphoblastic leukemia. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29467.	0.8	4
4	BK Polyomavirus Subtypes II and IV in Hematopoietic Cell Transplant Recipients. <i>Microbiology Resource Announcements</i> , 2022, 11, e0105321.	0.3	0
5	Unrelated donor \hat{I}^{\pm}/\hat{I}^2 T cell \hat{E} and B cell \hat{E} depleted HSCT for the treatment of pediatric acute leukemia. <i>Blood Advances</i> , 2022, 6, 1175-1185.	2.5	9
6	Comprehensive Serum Proteome Profiling of Cytokine Release Syndrome and Immune Effector Cell \hat{E} Associated Neurotoxicity Syndrome Patients with B-Cell ALL Receiving CAR T19. <i>Clinical Cancer Research</i> , 2022, 28, 3804-3813.	3.2	17
7	Identifying relapses and stem cell transplants in pediatric acute lymphoblastic leukemia using administrative data: Capturing national outcomes irrespective of trial enrollment. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28315.	0.8	1
8	Immune Reconstitution Following TCR \hat{I}^{\pm}/\hat{I}^2 /CD19-Depleted Hematopoietic Cell Transplantation for Hematologic Malignancy in Pediatric Patients. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 169.e1-169.e9.	0.6	9
9	Combined use of emapalumab and ruxolitinib in a patient with refractory hemophagocytic lymphohistiocytosis was safe and effective. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29026.	0.8	11
10	BK Polyomavirus (BKPyV) Infects and Injures Endothelium after Pediatric Hematopoietic Cell Transplant (HCT). <i>Transplantation and Cellular Therapy</i> , 2021, 27, S359-S361.	0.6	1
11	Extracellular Vesicle Proteome Reflects BK Viral Infection and Cystitis Status in Pediatric Hematopoietic Stem Cell Transplant (HSCT) Recipients. <i>Transplantation and Cellular Therapy</i> , 2021, 27, S355-S356.	0.6	0
12	Presentation acuity, induction mortality, and resource utilization in infants with acute leukemia. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28940.	0.8	1
13	Constrained chromatin accessibility in PU.1-mutated agammaglobulinemia patients. <i>Journal of Experimental Medicine</i> , 2021, 218, .	4.2	31
14	Standardization in the Diagnosis of Mixed Phenotype Acute Leukemia (MPAL): Semiquantitative, Universally Applicable Flow Cytometric Criteria for Immunophenotypic Lineage Assignment and Isolated MPO. <i>Blood</i> , 2021, 138, 4475-4475.	0.6	1
15	Veno-occlusive disease after high-dose busulfan \hat{E} melphalan in neuroblastoma. <i>Bone Marrow Transplantation</i> , 2020, 55, 531-537.	1.3	17
16	Transient atypical monocytosis after \hat{I}^{\pm}/\hat{I}^2 T cell \hat{E} depleted haploidentical hematopoietic stem cell transplantation. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28139.	0.8	1
17	The Natural History of BK Polyomavirus and the Host Immune Response After Stem Cell Transplantation. <i>Clinical Infectious Diseases</i> , 2020, 71, 3044-3054.	2.9	38
18	Partially CD3+-Depleted Unrelated and Haploidentical Donor Peripheral Stem Cell Transplantation Has Favorable Graft-versus-Host Disease and Survival Rates in Pediatric Hematologic Malignancy. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 493-501.	2.0	3

#	ARTICLE	IF	CITATIONS
19	Acute Kidney Injury in Children after Hematopoietic Cell Transplantation Is Associated with Elevated Urine CXCL10 and CXCL9. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1266-1272.	2.0	11
20	Celiac Disease Risk Determined By HLA-DQ Genotype Protects Against Gvhd in a Dose-Responsive Manner. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, S186.	2.0	0
21	Significance of minimal residual disease in pediatric mixed phenotype acute leukemia: a multicenter cohort study. <i>Leukemia</i> , 2020, 34, 1741-1750.	3.3	14
22	Differential Depletion of Bone Marrow Resident B-ALL after Systemic Administration of Endosomal TLR Agonists. <i>Cancers</i> , 2020, 12, 169.	1.7	5
23	Multisystem inflammatory syndrome in children and COVID-19 are distinct presentations of SARS-CoV-2. <i>Journal of Clinical Investigation</i> , 2020, 130, 5967-5975.	3.9	319
24	Outcomes of Human Adenovirus Infection and Disease in a Retrospective Cohort of Pediatric Hematopoietic Cell Transplant Recipients. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2019, 8, 317-324.	0.6	22
25	Outcomes of human adenovirus infection and disease in a retrospective cohort of pediatric solid organ transplant recipients. <i>Pediatric Transplantation</i> , 2019, 23, e13510.	0.5	7
26	Unintended consequences of evolution of the Common Terminology Criteria for Adverse Events. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27747.	0.8	40
27	Disparities in pediatric acute myeloid leukemia (AML) clinical trial enrollment. <i>Leukemia and Lymphoma</i> , 2019, 60, 2190-2198.	0.6	21
28	1762. Genotype Prevalence and Molecular Characteristics of Human Adenovirus in Pediatric Hematopoietic Stem Cell Transplant Recipients. <i>Open Forum Infectious Diseases</i> , 2019, 6, S648-S649.	0.4	0
29	Allogeneic hematopoietic stem cell transplantation in adolescent patients with chronic granulomatous disease. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 1052-1054.e2.	2.0	8
30	Comparable onâ€therapy mortality and supportive care requirements in Black and White patients following initial induction for pediatric acute myeloid leukemia. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27583.	0.8	10
31	Targeting EIF4E signaling with ribavirin in infant acute lymphoblastic leukemia. <i>Oncogene</i> , 2019, 38, 2241-2262.	2.6	29
32	The epidemiology of rasburicase use in paediatric patients with acute lymphoblastic leukaemia and nonâ€Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2019, 184, 684-688.	1.2	4
33	Area-Based Socioeconomic Disparities in Survival of Children with Newly Diagnosed Acute Myeloid Leukemia: A Report from the Children's Oncology Group. <i>Blood</i> , 2019, 134, 703-703.	0.6	1
34	Reduced Relapse Risk in Children with Acute Myeloid Leukemia (AML) Who Experience Septic Shock (SS). <i>Blood</i> , 2019, 134, 3496-3496.	0.6	0
35	Cost comparison by treatment arm and centerâ€level variations in cost and inpatient days on the phase III highâ€risk B acute lymphoblastic leukemia trial AALL0232. <i>Cancer Medicine</i> , 2018, 7, 3-12.	1.3	13
36	The role of peritoneal drainage in veno-occlusive disease in pediatric patients post hematopoietic stem cell transplant. <i>Bone Marrow Transplantation</i> , 2018, 53, 938-941.	1.3	1

#	ARTICLE	IF	CITATIONS
37	Hospital Variation in Intensive Care Resource Utilization and Mortality in Newly Diagnosed Pediatric Leukemia*. Pediatric Critical Care Medicine, 2018, 19, e312-e320.	0.2	10
38	Outcomes of matched sibling donor bone marrow transplantation in children using single-agent calcineurin inhibitors as prophylaxis for graft versus host disease. Pediatric Blood and Cancer, 2018, 65, e26726.	0.8	7
39	Absolute lymphocyte counts at end of induction correlate with distinct immune cell compartments in pediatric B cell precursor acute lymphoblastic leukemia. Cancer Immunology, Immunotherapy, 2018, 67, 225-236.	2.0	5
40	Nutritional risk factors predict severe acute graft-versus-host disease and early mortality in pediatric allogeneic hematopoietic stem cell transplantation. Pediatric Blood and Cancer, 2018, 65, e26853.	0.8	22
41	Generation of a multi-antigen-directed immune response for durable control of acute lymphoblastic leukemia. Leukemia, 2018, 32, 539-542.	3.3	4
42	Resource utilization and toxicities after single versus tandem autologous stem cell rescue in high-risk neuroblastoma using a national administrative database. Pediatric Blood and Cancer, 2018, 65, e27372.	0.8	4
43	BK Viremia is Common in Children after Allogeneic Hematopoietic Cell Transplant. Biology of Blood and Marrow Transplantation, 2018, 24, S87.	2.0	1
44	Opioid utilization among pediatric patients treated for newly diagnosed acute myeloid leukemia. PLoS ONE, 2018, 13, e0192529.	1.1	16
45	Checkpoint Inhibitors Augment CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy in Relapsed B-Cell Acute Lymphoblastic Leukemia. Blood, 2018, 132, 556-556.	0.6	106
46	Minimal Residual Disease Risk-Stratification in Pediatric Mixed Phenotype Acute Leukemia: Results of a Multi-Center Cohort Study. Blood, 2018, 132, 558-558.	0.6	3
47	Renal Complications Associated with HSCT. , 2018, , 327-332.		0
48	Using Administrative Data to Identify Relapse and Hematopoietic Stem Cell Transplantation (HSCT) in Children with Acute Lymphoblastic Leukemia (ALL): Validation at Two Centers and Incidence Estimation in a National Cohort. Blood, 2018, 132, 624-624.	0.6	0
49	A Novel Approach to Identifying Septic Shock (SS) in Children with Acute Lymphoblastic Leukemia (ALL) Using Pediatric Health Information System (PHIS) Data: Methods Validation and Incidence Estimation in a National Cohort. Blood, 2018, 132, 3597-3597.	0.6	0
50	Clinical Outcomes in Pediatric Mixed Phenotype Acute Leukemia (MPAL) Differ Depending on Disease Classification Criteria; A Multi-Center Cohort Study. Blood, 2018, 132, 4080-4080.	0.6	0
51	Increased Disease Burden Among Black Children Compared to White Children with Newly Diagnosed Acute Myeloid Leukemia. Blood, 2018, 132, 369-369.	0.6	3
52	Using electronic medical record data to report laboratory adverse events. British Journal of Haematology, 2017, 177, 283-286.	1.2	31
53	Single-Agent Calcineurin-Inhibitor (CNI) for the Prevention of Graft Versus Host Disease (GVHD) in Pediatric Patients Undergoing HLA-Identical Sibling Bone Marrow Transplant (BMT). Biology of Blood and Marrow Transplantation, 2017, 23, S366.	2.0	0
54	Immune Reconstitution In Six Adolescents With Chronic Granulomatous Disease (CGD) Following Hematopoietic Stem Cell Transplant (HSCT). Journal of Allergy and Clinical Immunology, 2017, 139, AB111.	1.5	0

#	ARTICLE	IF	CITATIONS
55	IFN γ directly inhibits murine B-cell precursor leukemia-initiating cell proliferation early in life. <i>European Journal of Immunology</i> , 2017, 47, 892-899.	1.6	13
56	The role of acuity of illness at presentation in early mortality in black children with acute myeloid leukemia. <i>American Journal of Hematology</i> , 2017, 92, 141-148.	2.0	29
57	Complications preceding early deaths in Black and White children with acute myeloid leukemia. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26712.	0.8	4
58	Center-level variation in accuracy of adverse event reporting in a clinical trial for pediatric acute myeloid leukemia: a report from the Children's Oncology Group. <i>Haematologica</i> , 2017, 102, e340-e343.	1.7	4
59	Creation of a pediatric mature B-cell non-Hodgkin lymphoma cohort within the Pediatric Health Information System Database. <i>PLoS ONE</i> , 2017, 12, e0186960.	1.1	5
60	Comparative Effectiveness of Cidofovir Preemptive Therapy for Human Adenovirus Infection in Pediatric Hematopoietic Cell Transplant Recipients. <i>Open Forum Infectious Diseases</i> , 2017, 4, S715-S715.	0.4	0
61	Abstract A51: Early-life infection delays B cell precursor leukemia onset in Eu-Ret mice via an IL-23-dependent depletion of leukemia-initiating cells. , 2017, , .		0
62	Bortezomib Inpatient Prescribing Practices in Free-Standing Children's Hospitals in the United States. <i>PLoS ONE</i> , 2016, 11, e0151362.	1.1	5
63	Supportive care utilization and treatment toxicity in children with Down syndrome and acute lymphoid leukaemia at free-standing paediatric hospitals in the United States. <i>British Journal of Haematology</i> , 2016, 174, 591-599.	1.2	14
64	Resource Utilization and Toxicities After Carboplatin/Etoposide/Melphalan and Busulfan/Melphalan for Autologous Stem Cell Rescue in High-Risk Neuroblastoma Using a National Administrative Database. <i>Pediatric Blood and Cancer</i> , 2016, 63, 901-907.	0.8	8
65	Early discharge as a mediator of greater ICU-level care requirements in patients not enrolled on the AAML0531 clinical trial: a Children's Oncology Group report. <i>Cancer Medicine</i> , 2016, 5, 2412-2416.	1.3	4
66	Unrelated and Haploidentical Hematopoietic Stem Cell Transplantation (HSCT) Using TCR β 2+CD3+ Depletion in Pediatric Patients with Hematologic Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, S244-S245.	2.0	0
67	Inhibition of precursor B-cell malignancy progression by toll-like receptor ligand-induced immune responses. <i>Leukemia</i> , 2016, 30, 2116-2119.	3.3	15
68	Newborn Screening for SCID Is Associated with a Shorter Interval from Diagnosis to Transplant. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 137, AB218.	1.5	1
69	Favorable Chronic Graft-Versus-Host-Disease (GVHD), Event-Free (EFS), and Overall Survival (OS) Rates Following Partially CD3-Depleted Alternative Donor Peripheral Stem Cell Transplantation (PSCT) for Pediatric Hematologic Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, S62-S63.	2.0	1
70	Hematopoietic Stem Cell Transplantation (HSCT) for Acute Lymphoblastic Leukemia (ALL) in First Remission (CR1): A Single-Institution Retrospective Cohort Study Demonstrating Excellent Event-Free (EFS) and Overall Survival (OS). <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, S238-S239.	2.0	0
71	Low Body Mass Index and a Composite Nutritional Risk Variable Predict High-Grade Acute Graft-Versus-Host Disease (aGVHD) and Early Mortality in Pediatric Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT). <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, S259-S260.	2.0	1
72	Toxicities of busulfan/melphalan versus carboplatin/etoposide/melphalan for high-dose chemotherapy with stem cell rescue for high-risk neuroblastoma. <i>Bone Marrow Transplantation</i> , 2016, 51, 1204-1210.	1.3	36

#	ARTICLE	IF	CITATIONS
73	Low rates of pregnancy screening in adolescents before teratogenic exposures in a national sample of children's hospitals. <i>Cancer</i> , 2016, 122, 3394-3400.	2.0	8
74	Sirolimus is effective in relapsed/refractory autoimmune cytopenias: results of a prospective multi-institutional trial. <i>Blood</i> , 2016, 127, 17-28.	0.6	165
75	CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity. <i>Nature Communications</i> , 2016, 7, 12320.	5.8	325
76	Predicting Optimal Timing of Halting IMiG Therapy after HSCT for SCID. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 137, AB276.	1.5	0
77	Volumeâ€œOutcome Relationships in Pediatric Acute Lymphoblastic Leukemia: Association Between Hospital Pediatric and Pediatric Oncology Volume With Mortality and Intensive Care Resources During Initial Therapy. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 404-410.e1.	0.2	11
78	Treatment of Osteonecrosis in Children and Adolescents With Acute Lymphoblastic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 223-229.e2.	0.2	12
79	Accuracy of Adverse Event Ascertainment in Clinical Trials for Pediatric Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2016, 34, 1537-1543.	0.8	47
80	A comparison of discharge strategies after chemotherapy completion in pediatric patients with acute myeloid leukemia: a report from the Childrenâ€™s Oncology Group. <i>Leukemia and Lymphoma</i> , 2016, 57, 1567-1574.	0.6	13
81	A comparison of resource utilization following chemotherapy for acute myeloid leukemia in children discharged versus children that remain hospitalized during neutropenia. <i>Cancer Medicine</i> , 2015, 4, 1356-1364.	1.3	17
82	Comparison of administrative/billing data to expected protocolâ€œmandated chemotherapy exposure in children with acute myeloid leukemia: A report from the Children's Oncology Group. <i>Pediatric Blood and Cancer</i> , 2015, 62, 1184-1189.	0.8	12
83	Comparison of in-patient costs for children treated on the AAMLO531 clinical trial: A report from the Children's Oncology Group. <i>Pediatric Blood and Cancer</i> , 2015, 62, 1775-1781.	0.8	21
84	Burden of Influenza-Related Hospitalizations and Attributable Mortality in Pediatric Acute Lymphoblastic Leukemia. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2015, 4, 290-296.	0.6	7
85	Dexrazoxane exposure and risk of secondary acute myeloid leukemia in pediatric oncology patients. <i>Pediatric Blood and Cancer</i> , 2015, 62, 704-709.	0.8	65
86	Merging Childrenâ€™s Oncology Group Data with an External Administrative Database Using Indirect Patient Identifiers: A Report from the Childrenâ€™s Oncology Group. <i>PLoS ONE</i> , 2015, 10, e0143480.	1.1	16
87	Racial Disparities in Pediatric Acute Myeloid Leukemia during Induction. <i>Blood</i> , 2015, 126, 530-530.	0.6	0
88	439Infection Risk in Pediatric Stem Cell Transplant Recipients for Hemophagocytic Lymphohistiocytosis vs Acute Leukemia. <i>Open Forum Infectious Diseases</i> , 2014, 1, S167-S167.	0.4	0
89	Patient and hospital factors associated with induction mortality in acute lymphoblastic leukemia. <i>Pediatric Blood and Cancer</i> , 2014, 61, 846-852.	0.8	21
90	Association of Weekend Admission With Hospital Length of Stay, Time to Chemotherapy, and Risk for Respiratory Failure in Pediatric Patients With Newly Diagnosed Leukemia at Freestanding US Childrenâ€™s Hospitals. <i>JAMA Pediatrics</i> , 2014, 168, 925.	3.3	24

#	ARTICLE	IF	CITATIONS
91	Outcome of Pediatric Acute Myeloid Leukemia Patients Receiving Intensive Care in the United States. <i>Pediatric Critical Care Medicine</i> , 2014, 15, 112-120.	0.2	48
92	Variation in Risk of Hospital-Onset Clostridium difficile Infection Across β -Lactam Antibiotics in Children With New-Onset Acute Lymphoblastic Leukemia. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2014, 3, 329-335.	0.6	18
93	Induction mortality, ATRA administration, and resource utilization in a nationally representative cohort of children with acute promyelocytic leukemia in the United States from 1999 to 2009. <i>Pediatric Blood and Cancer</i> , 2014, 61, 68-73.	0.8	11
94	Antifungal Prophylaxis Associated With Decreased Induction Mortality Rates and Resources Utilized in Children With New-Onset Acute Myeloid Leukemia. <i>Clinical Infectious Diseases</i> , 2014, 58, 502-508.	2.9	18
95	Establishing a high-risk neuroblastoma cohort using the pediatric health information system database. <i>Pediatric Blood and Cancer</i> , 2014, 61, 1129-1131.	0.8	15
96	Establishment of an 11-Year Cohort of 8733 Pediatric Patients Hospitalized at United States Free-standing Children's Hospitals With De Novo Acute Lymphoblastic Leukemia From Health Care Administrative Data. <i>Medical Care</i> , 2014, 52, e1-e6.	1.1	42
97	Abstract B33: Toll-like receptor ligands delay acute lymphoblastic leukemia onset via depletion of pre-leukemic cells. , 2014, , .		0
98	Abstract B20: Innate and adaptive immune control of neoantigen-bearing acute lymphoblastic leukemia (ALL) enhanced by epitope spread. , 2014, , .		0
99	Comparison of Resource Utilization in Children Discharged Versus Children That Remain Hospitalized Following Chemotherapy for Acute Myeloid Leukemia. <i>Blood</i> , 2014, 124, 3697-3697.	0.6	0
100	Pediatric Hospital Volume and Induction Mortality in Pediatric Acute Lymphoblastic Leukemia (ALL). <i>Blood</i> , 2014, 124, 2653-2653.	0.6	0
101	Resource Utilization and Cost Analysis By Treatment Arm on the Children's Oncology Group AALL0232 Phase 3 High-Risk B-Precursor Acute Lymphoblastic Leukemia Trial: A Report from the Children's Oncology Group. <i>Blood</i> , 2014, 124, 210-210.	0.6	0
102	Epitope Spreading Is Required for Long-Term Protection Against Acute Lymphoblastic Leukemia. <i>Blood</i> , 2014, 124, 3717-3717.	0.6	0
103	Treatment Toxicity and Supportive Care Utilization in Children with Down Syndrome and Acute Lymphoid Leukemia at Free-Standing Pediatric Hospitals in the United States. <i>Blood</i> , 2014, 124, 553-553.	0.6	1
104	Patient Factors Associated with Enrollment on an Acute Myeloid Leukemia Phase III Clinical Trial: A Report from the Children's Oncology Group. <i>Blood</i> , 2014, 124, 2286-2286.	0.6	0
105	Variation in hospital antibiotic prescribing practices for children with acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2013, 54, 1633-1639.	0.6	21
106	Assembly of a cohort of children treated for acute myeloid leukemia at free-standing children's hospitals in the United States using an administrative database. <i>Pediatric Blood and Cancer</i> , 2013, 60, 508-511.	0.8	33
107	Leveraging Administrative Data to Monitor Rituximab Use in 2875 Patients at 42 Freestanding Children's Hospitals across the United States. <i>Journal of Pediatrics</i> , 2013, 162, 1252-1258.e1.	0.9	53
108	Dexamethasone use in pediatric patients with acute lymphoblastic or myeloid leukemia from 1999 and 2009: Analysis of a national cohort of patients in the pediatric health information systems database. <i>Pediatric Blood and Cancer</i> , 2013, 60, 616-620.	0.8	35

#	ARTICLE	IF	CITATIONS
109	A pilot study of tandem high-dose chemotherapy with stem cell rescue as consolidation for high-risk neuroblastoma: Children's Oncology Group study ANBL00P1. <i>Bone Marrow Transplantation</i> , 2013, 48, 947-952.	1.3	43
110	Induction mortality and resource utilization in children treated for acute myeloid leukemia at free-standing pediatric hospitals in the United States. <i>Cancer</i> , 2013, 119, 1916-1923.	2.0	37
111	Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy. <i>Blood</i> , 2013, 121, 5154-5157.	0.6	524
112	Zoonotic infections in pediatric patients with acute leukemia. <i>Pediatric Blood and Cancer</i> , 2013, 60, E160-E162.	0.8	3
113	Avascular Necrosis(AVN) and Surgical Intervention In Pediatric Acute Lymphoblastic Leukemia(ALL): A Retrospective Cohort Analysis From The Pediatric Health Information Systems (PHIS). <i>Blood</i> , 2013, 122, 1689-1689.	0.6	1
114	Targeting mTOR Signaling Leads To Complete and Durable Responses In Children With Multi-Lineage Autoimmune Cytopenias, Including ALPS, SLE, Evans and CVID. <i>Blood</i> , 2013, 122, 330-330.	0.6	2
115	Abstract 3972: Carpet bombing with CARs: Influence of dose, timing, lymphodepletion and costimulatory domain on efficacy of mRNA engineered anti-CD19 Chimeric Antigen Receptor T cells in preclinical xenograft models.. , 2013, , .		0
116	Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia. <i>Blood</i> , 2012, 120, 3510-3518.	0.6	263
117	Merging of the National Cancer Institute's funded cooperative oncology group data with an administrative data source to develop a more effective platform for clinical trial analysis and comparative effectiveness research: a report from the Children's Oncology Group. <i>Pharmacoepidemiology and Drug Safety</i> . 2012, 21, 37-43.	0.9	44
118	Mortality and Resource Utilization in Children with De Novo Acute Myeloid Leukemia Treated with Chemotherapy and Gemtuzumab Ozogamicin in the United States. <i>Blood</i> , 2012, 120, 4283-4283.	0.6	0
119	Variability in Antifungal Use for Pediatric Acute Myeloid Leukemia At Children's Hospitals Across the United States. <i>Blood</i> , 2012, 120, 4278-4278.	0.6	1
120	A Novel Model of Immune-Mediated Disease Equilibrium in Acute Lymphoblastic Leukemia. <i>Blood</i> , 2012, 120, 3540-3540.	0.6	0
121	Pediatric leukemia predisposition syndromes: clues to understanding leukemogenesis. <i>Cancer Genetics</i> , 2011, 204, 227-244.	0.2	79
122	Noninvasive bioluminescent imaging of primary patient acute lymphoblastic leukemia: a strategy for preclinical modeling. <i>Blood</i> , 2011, 118, e112-e117.	0.6	49
123	Dexrazoxane Use in Pediatric Patients with Acute Lymphoblastic or Myeloid Leukemia: Analysis of a National Cohort of Patients in the Pediatric Health Information Systems Database From 1999 to 2009. <i>Blood</i> , 2011, 118, 4242-4242.	0.6	15
124	Merging of Children's Oncology Group and Pediatric Health Information Systems Data to Determine Resource Utilization and Treatment Costs on AAML0531: A Report From the Children's Oncology Group. <i>Blood</i> , 2011, 118, 2617-2617.	0.6	0
125	Intrathecal Liposomal Cytarabine in Relapsed or Refractory Infant and Pediatric Leukemias: The Children's Hospital of Philadelphia Experience and Review of the Literature. <i>Journal of Pediatric Hematology/Oncology</i> , 2010, 32, e349-e352.	0.3	8
126	Identifying autoimmune lymphoproliferative syndrome in children with Evans syndrome: a multi-institutional study. <i>Blood</i> , 2010, 115, 2142-2145.	0.6	84

#	ARTICLE	IF	CITATIONS
127	Secondary adrenal insufficiency in an infant after intrathecal triple chemotherapy. <i>Pediatric Blood and Cancer</i> , 2010, 55, 386-389.	0.8	3
128	Advances in the management and understanding of autoimmune lymphoproliferative syndrome (ALPS). <i>British Journal of Haematology</i> , 2010, 148, 205-216.	1.2	115
129	Salvage therapy with nelarabine, etoposide, and cyclophosphamide in relapsed/refractory paediatric T-cell lymphoblastic leukaemia and lymphoma. <i>British Journal of Haematology</i> , 2010, 150, 345-351.	1.2	74
130	Bioluminescent Tracking of Human and Mouse Acute Lymphoblastic Leukemia Reveals Potent Immunogenicity of Luciferase In Some Preclinical Models of Leukemia. <i>Blood</i> , 2010, 116, 2140-2140.	0.6	1
131	Induction Mortality In Pediatric Acute Lymphoblastic Leukemia (ALL): a Retrospective Cohort Analysis From the Pediatric Health Systems Information (PHIS) Database, 1999-2009. <i>Blood</i> , 2010, 116, 3239-3239.	0.6	1
132	Treatment with sirolimus results in complete responses in patients with autoimmune lymphoproliferative syndrome. <i>British Journal of Haematology</i> , 2009, 145, 101-106.	1.2	151
133	Long-term protection from syngeneic acute lymphoblastic leukemia by CpG ODN-mediated stimulation of innate and adaptive immune responses. <i>Blood</i> , 2009, 114, 2459-2466.	0.6	36
134	Novel molecular and cellular therapeutic targets in acute lymphoblastic leukemia and lymphoproliferative disease. <i>Immunologic Research</i> , 2008, 42, 84-105.	1.3	35
135	Targeting Notch signaling in autoimmune and lymphoproliferative disease. <i>Blood</i> , 2008, 111, 705-714.	0.6	68
136	mTOR inhibitors are synergistic with methotrexate: an effective combination to treat acute lymphoblastic leukemia. <i>Blood</i> , 2008, 112, 2020-2023.	0.6	117
137	CpG Oligonucleotides Induce Anti-Leukemia Activity in a Syngeneic Murine Model of Acute Lymphoblastic Leukemia.. <i>Blood</i> , 2007, 110, 2830-2830.	0.6	0
138	Heritable predisposition to childhood hematologic malignancies. , 0, , 276-308.		0